/NURPF
NURPF Stock - Neuren Pharmaceuticals Limited
Healthcare|BiotechnologyOTC
$12.88+0.00%
+$0.00 (+0.00%) • Dec 19
64
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.83
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).70
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.46
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+10.0%upside
Target: $14.17
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for NURPF
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$12.76 – $13.01
TARGET (TP)$14.82
STOP LOSS$11.85
RISK/REWARD1:1.9
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta1.85
52W High$14.80
52W Low$6.60
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $216.83M | $231.93M | $14.55M | $3.20M | $717,000 |
| Gross Profit | $183.86M | $205.17M | $14.54M | $3.19M | $711,000 |
| Gross Margin | 84.8% | 88.5% | 99.9% | 99.7% | 99.2% |
| Operating Income | $146.19M | $172.49M | $-1,596,000 | $-17,749,000 | $-16,572,000 |
| Net Income | $142.04M | $157.08M | $184,000 | $-7,794,000 | $-9,193,000 |
| Net Margin | 65.5% | 67.7% | 1.3% | -243.8% | -1282.1% |
| EPS | $1.09 | $1.24 | $0.00 | $-0.07 | $-0.09 |
Company Overview
Neuren Pharmaceuticals Limited, a biopharmaceutical company, develops drugs for the treatment of neurological disorders. Its lead product is trofinetide, which is in Phase III clinical trial for the treatment of Rett syndrome, as well as has completed Phase II clinical trial to treat Fragile X syndrome. The company also develops NNZ-2591, which has completed Phase I clinical trial for the treatment of Phelan-McDermid, Angelman, Pitt Hopkins, and Prader-Will syndromes. In addition, it provides development services; and holds loan funded shares. The company was incorporated in 2001 and is based in Camberwell, Australia.
Visit WebsiteLoading analyst ratings...
Earnings History & Surprises
NURPFBeat Rate
20%
Last 5 quarters
Avg Surprise
-9.2%
EPS vs Estimate
Beats / Misses
1/4
Last 12 quarters
Latest EPS
$0.08
Q3 2025
EPS Surprise History
Q4 21
No data
Q2 22
No data
Q4 22
No data
Q2 23
+14.5%
$0.24vs$0.21
Q1 24
-15.1%
$0.57vs$0.67
Q3 24
-44.0%
$0.04vs$0.07
Q1 25
-0.9%
$0.64vs$0.64
Q3 25
-0.3%
$0.08vs$0.08
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Feb 25, 2026 | — | — | — | — |
Q3 2025 | Aug 26, 2025 | $0.08 | $0.08 | -0.3% | ✗ MISS |
Q1 2025 | Feb 27, 2025 | $0.64 | $0.64 | -0.9% | ✗ MISS |
Q3 2024 | Aug 27, 2024 | $0.07 | $0.04 | -44.0% | ✗ MISS |
Q1 2024 | Feb 29, 2024 | $0.67 | $0.57 | -15.1% | ✗ MISS |
Q2 2023 | Jun 30, 2023 | $0.21 | $0.24 | +14.5% | ✓ BEAT |
Q4 2022 | Dec 31, 2022 | — | $0.04 | — | — |
Q2 2022 | Jun 30, 2022 | — | $-0.04 | — | — |
Q4 2021 | Dec 31, 2021 | — | $0.00 | — | — |
Q2 2021 | Jun 30, 2021 | — | $-0.05 | — | — |
Q4 2020 | Dec 31, 2020 | — | $-0.03 | — | — |
Q2 2020 | Jun 30, 2020 | — | $-0.03 | — | — |
Q4 2019 | Dec 31, 2019 | — | $-0.02 | — | — |
Q2 2019 | Jun 30, 2019 | — | $-0.06 | — | — |
Q4 2018 | Dec 31, 2018 | — | $0.05 | — | — |
Q2 2018 | Jun 30, 2018 | — | $-0.03 | — | — |
Q1 2018 | Feb 28, 2018 | — | $0.05 | — | — |
Q3 2017 | Aug 24, 2017 | — | $-0.03 | — | — |
Q1 2017 | Feb 23, 2017 | — | $-0.04 | — | — |
Q3 2016 | Aug 30, 2016 | — | $-0.06 | — | — |
Latest News
Loading news...
Frequently Asked Questions about NURPF
What is NURPF's current stock price?
Neuren Pharmaceuticals Limited (NURPF) is currently trading at $12.88 per share. The stock has moved +0.00% today.
What is the analyst price target for NURPF?
No analyst price targets are currently available for this stock.
What sector is Neuren Pharmaceuticals Limited in?
Neuren Pharmaceuticals Limited operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the OTC exchange.
What is NURPF's market cap?
Neuren Pharmaceuticals Limited has a market capitalization of $1.60 billion, making it a small-cap company.
Does NURPF pay dividends?
No, Neuren Pharmaceuticals Limited does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorANEB
Anebulo Pharmaceuticals, Inc.
$2.17
Mkt Cap: $0.1B
ASMB
Assembly Biosciences, Inc.
$35.26
Mkt Cap: $0.3B
AVTE
Aerovate Therapeutics, Inc.
$2.68
Mkt Cap: $0.1B
CERE
Cerevel Therapeutics Holdings, Inc.
$44.96
Mkt Cap: $8.2B
CMPX
Compass Therapeutics, Inc.
$4.99
Mkt Cap: $0.7B
CRNX
Crinetics Pharmaceuticals, Inc.
$48.01
Mkt Cap: $4.6B
CSBR
Champions Oncology, Inc.
$7.22
Mkt Cap: $0.1B
CYT
Cyteir Therapeutics, Inc.
$3.02
Mkt Cap: $0.1B
ELVN
Enliven Therapeutics, Inc.
$16.87
Mkt Cap: $1.0B
ENOB
Enochian Biosciences, Inc.
$0.71
Mkt Cap: $0.0B
Explore stocks similar to NURPF for comparison